Company intelligence / Profile preview
MycRx
Melbourne, Victoria, Australiamycrxpharma.com ↗
- Ownership
- Private
- Employees
- ~14
- Development stage
- Preclinical
01
Overview
MycRx compounds display potent cellular Myc target engagement driving profound transcriptional inhibition and on-target mechanistic profiles, resulting in compelling anti-cancer activity. The company has built a comprehensive dataset optimizing existing late lead compounds to candidate selection with potent and selective activity, good PK properties in rodents, including oral bioavailability[3][4].
- Therapeutic areas
- Oncology
- Modalities
- Small molecule inhibitors
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
CSIROPeter MacCallum Cancer Centre (PMCC)[4]
Beyond the preview
Go deeper on MycRx.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MycRx.